[PGI8] Cost-effectiveness analysis of rotavirus vaccination programme in the UK

[PGI8] Cost-effectiveness analysis of rotavirus vaccination programme in the UK

2006 Value in health

Largeron, N. | Trichard, M. | Miadi-Fargier, H. | Trancard, A. | D'Ausilio, A. | Chicoye, A. | Volume: 9, Issue: 6, Pages: A243-A244, analysis, cost-effectiveness analysis, Vaccination, methods, model, utilization,

OBJECTIVES: A pentavalent rotavirus vaccine to prevent
rotavirus gastroenteritis (RVGE) in children will soon become
available. The objective of the study reported here was to assess
the health outcomes and the economic impact in the UK of a RV
vaccination programme vs no programme. METHODS: A birth
cohort was followed up to age 5 using a cohort model. Epidemiological
parameters were taken from the REVEAL study (a
prospective epidemiological study conducted in the UK, 2004-
2005) and from literature. Costs were assessed from NHS and
societal perspectives by combining health care resource utilization
collected in REVEAL study and unit costs from official
sources. ITT effectiveness of the vaccine was taken from a large
worldwide clinical trial (70,000 children). Health outcomes
included home care cases, telephone consultations, GP/Accident&Emergency
department visits, hospitalisations and nosocomial
infections. A sensitivity analysis was performed varying
the cost of the RV vaccine course between £80 and £100.
RESULTS: The model estimates that the introduction of a RV
vaccination programme with the pentavalent RV vaccine (90%
coverage rate) would reduce the RVGE burden by 75% in the
UK: 102,290 home care cases, 25,570 telephone consultations,
83,220 GP visits, 5660 Accident&Emergency department visits,
12,220 hospitalisations and 5040 nosocomial infections could be
avoided. The RVGE cost was estimated at £29m and £69m from
NHS and societal perspectives respectively. The introduction of
a RV vaccination programme would reduce the RVGE cost by
about 75% in both perspectives. For a vaccine course ranging
from £80 to £100, the RV vaccination programme is associated
with an incremental cost-effectiveness ratio that varies from
£2460 to £3515 and from £0 to £1050 per hospitalization
averted from NHS and societal perspectives respectively.
CONCLUSION: This study suggests that a RV vaccination programme
would have a substantial impact in reducing the important
burden of RVGE and associated costs in the UK.

https://www.doi.org/10.1016/S1098-3015(10)63332-3